Abstract
Aripirazole is a novel antipsychotic that functions as a partial agonist at the dopamine D2 receptor and, thus, might theoretically worsen psychosis. We report a series of four clinical cases of exacerbation of psychosis related to initiation of aripiprazole therapy. Cases 1 and 2 demonstrated the worsening of psychosis following initiation of aripiprazole (15-30 mg daily) while tapering off the previous atypical antipsychotic. Cases 3 and 4 demonstrated worsening of psychosis following the addition of aripiprazole (15-30 mg daily) to an atypical antipsychotic. In two out of the four cases, discontinuation of arpiprazole resulted In improvement of psychotic symptoms. Although the cases presented are suggestive of a relationship between initiation of aripiprazole therapy and worsening of psychosis, further research is needed to clarify any potential association.
| Original language | English |
|---|---|
| Pages (from-to) | 45-48 |
| Number of pages | 4 |
| Journal | International Clinical Psychopharmacology |
| Volume | 19 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2004 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Psychiatry and Mental health
- Pharmacology (medical)
- Neuroscience(all)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Aripiprazole possibly worsens psychosis. / Ramaswamy, Sriram; Vijay, Dewan; William, Marcil; Sattar, S. Pirzada; Praveen, Fernandes; Petty, Frederick.
In: International Clinical Psychopharmacology, Vol. 19, No. 1, 01.2004, p. 45-48.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Aripiprazole possibly worsens psychosis
AU - Ramaswamy, Sriram
AU - Vijay, Dewan
AU - William, Marcil
AU - Sattar, S. Pirzada
AU - Praveen, Fernandes
AU - Petty, Frederick
PY - 2004/1
Y1 - 2004/1
N2 - Aripirazole is a novel antipsychotic that functions as a partial agonist at the dopamine D2 receptor and, thus, might theoretically worsen psychosis. We report a series of four clinical cases of exacerbation of psychosis related to initiation of aripiprazole therapy. Cases 1 and 2 demonstrated the worsening of psychosis following initiation of aripiprazole (15-30 mg daily) while tapering off the previous atypical antipsychotic. Cases 3 and 4 demonstrated worsening of psychosis following the addition of aripiprazole (15-30 mg daily) to an atypical antipsychotic. In two out of the four cases, discontinuation of arpiprazole resulted In improvement of psychotic symptoms. Although the cases presented are suggestive of a relationship between initiation of aripiprazole therapy and worsening of psychosis, further research is needed to clarify any potential association.
AB - Aripirazole is a novel antipsychotic that functions as a partial agonist at the dopamine D2 receptor and, thus, might theoretically worsen psychosis. We report a series of four clinical cases of exacerbation of psychosis related to initiation of aripiprazole therapy. Cases 1 and 2 demonstrated the worsening of psychosis following initiation of aripiprazole (15-30 mg daily) while tapering off the previous atypical antipsychotic. Cases 3 and 4 demonstrated worsening of psychosis following the addition of aripiprazole (15-30 mg daily) to an atypical antipsychotic. In two out of the four cases, discontinuation of arpiprazole resulted In improvement of psychotic symptoms. Although the cases presented are suggestive of a relationship between initiation of aripiprazole therapy and worsening of psychosis, further research is needed to clarify any potential association.
UR - http://www.scopus.com/inward/record.url?scp=1642452858&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642452858&partnerID=8YFLogxK
U2 - 10.1097/00004850-200401000-00009
DO - 10.1097/00004850-200401000-00009
M3 - Article
VL - 19
SP - 45
EP - 48
JO - International Clinical Psychopharmacology
JF - International Clinical Psychopharmacology
SN - 0268-1315
IS - 1
ER -